Global Reach & Presence

Sri Lanka-2017

Scotmann maintains an established and sustained presence in Sri Lanka as an active commercial market, supported by over five years of continuous operations. The market is managed through an authorized distributor model, complemented by participation in government tenders, enabling effective market access and consistent execution. Scotmann’s portfolio in Sri Lanka focuses on Cardiovascular & Diabetes segments, aligned with local healthcare needs. Products are positioned as branded generics and differentiated formulations, supporting long-term brand development and therapeutic value. Multiple products are currently approved, with additional regulatory submissions planned for 2026. The active dossier base exceeds ten registrations, reflecting strong regulatory depth and continuity. Scotmann’s local value contribution is driven by a commitment to regulatory compliance and a reliable supply framework, ensuring uninterrupted access to quality medicines.

Afghanistan-2021

Afghanistan is an active commercial market for Scotmann, with over five years of continuous engagement. Operations are managed through an authorized distributor model, supporting sustained commercial supply and market continuity. The portfolio covers Anti-infectives, CNS, Gastrointestinal, Cardiovascular, and Vitamins & Nutrition, aligned with essential healthcare needs. Products are positioned as branded generics and differentiated formulations. Several products are approved by the local regulatory authority, with additional submissions planned for 2026. The current dossier base includes up to five approved products. The market is supported through regular commercial shipments, with Scotmann placing primary emphasis on maintaining reliable supply to ensure consistent access to essential medicines.

Cambodia-2022

Cambodia represents an active commercial market for Scotmann, with a growing footprint developed over the past three years. Operations are conducted through an authorized distributor, providing structured market access and regulatory alignment. The portfolio primarily focuses on Gastrointestinal therapies and Cardiovascular & Diabetes segments, tailored to local prescribing practices and demand patterns. Products are positioned within the branded generics segment to support sustainable market development. Several products are approved by the Ministry of Health, while additional dossiers are currently under regulatory review. The active pipeline comprises approximately six to ten dossiers. Scotmann contributes to the Cambodian market through strong regulatory discipline and dependable product supply, supporting continuity of care.

Mauritania

Mauritania is a strategic pipeline market for Scotmann, with market entry activities initiated within the past two years. The planned operating model is based on collaboration with an authorized distributor to ensure compliance with local regulatory and commercial requirements. The intended portfolio spans Anti-infectives, CNS, Gastrointestinal, Cardiovascular, and Vitamins & Nutrition, addressing essential therapeutic needs. Products will be positioned as branded generics and differentiated formulations. Regulatory dossiers are currently under review with the Ministry of Health, with more than ten submissions forming the initial entry pipeline. Scotmann’s approach in Mauritania emphasizes regulatory compliance and the establishment of a reliable and sustainable supply framework to support future commercial operations.

Benin

Benin is positioned as a pre-entry pipeline market for Scotmann, with preparatory regulatory and commercial activities underway over the past two years. The market strategy is centred on partnering with an authorized distributor to facilitate structured market entry. The intended therapeutic scope includes Anti-infectives, CNS, Gastrointestinal, Cardiovascular, and Vitamins & Nutrition. Products will be introduced as branded generics and differentiated formulations in line with local healthcare requirements. Regulatory dossiers are currently under review with the Ministry of Health, with an active pipeline exceeding ten submissions. Scotmann’s market entry approach in Benin is founded on strong regulatory compliance and the development of a dependable supply mechanism.